Abstract
Purpose: Hematological malignancies have become a significant health concern due to their increasing incidence. This highlights the need for the identification of novel biomarkers and therapeutic targets. Budding Uninhibited by Benzimidazoles 3 (BUB3) is a mitotic checkpoint protein that regulates chromosome segregation during mitosis. Dysregulation of BUB3-related pathways has been associated with tumor development and disease progression. This study aims to investigate the expression levels of BUB3 in Burkitt lymphoma (Raji) and T-cell leukemia (Jurkat) cell lines and to evaluate its potential as a biomarker and therapeutic target in hematological cancers.
Materials and Methods: BUB3 expression levels were analyzed in various cancer cell lines using the BioGPS database. Additionally, a protein-protein interaction (PPI) network was constructed via the STRING database to evaluate BUB3's interactions with cell cycle-related molecules. To validate the bioinformatics results, BUB3 expression was quantitatively measured by RT-qPCR in Raji, Jurkat, and control HaCaT (human keratinocyte) cell lines.
Results: RT-qPCR analysis revealed significantly was increased BUB3 expression in Raji and Jurkat cells compared to the HaCaT control group. PPI analysis indicated that BUB3 interacts with proteins involved in cell cycle regulation, apoptosis, and proliferation.
Conclusion: BUB3 is overexpressed in hematological malignancies and may play a role in tumor biology. Therefore, BUB3 could serve as a potential prognostic biomarker and therapeutic target. Further in vivo studies are needed to confirm its clinical relevance.